Compare Ascendis Pharma A/S (ASND) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs T-Mobile Us Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while T-Mobile Us Inc trades at $188.62 (market cap $203.03B). The key difference: T-Mobile Us Inc is far larger — about 11.4× Ascendis Pharma A/S's market cap, and T-Mobile Us Inc pays a 2.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TMUS | |
|---|---|---|
Market Cap | $17.74B | $203.03B |
Sector | Health | Media |
52-Week High | $277.18 | $259.01 |
52-Week Low | $163.32 | $167.65 |
Enterprise Value | $18.11B | $320.73B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
T-Mobile US (TMUS) trades at $187.61, up 3.38% on the day, with a neutral technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B, net income of $10.99B, and consistent cash flow generation. Recent leadership changes and competitive threats from SpaceX's potential market entry are key developments. Valuation metrics include a P/E of 19.94 and P/S of 2.32, while the consensus price target is $244.50, suggesting significant upside potential.
The outlook for TMUS is positive due to strong earnings beats, healthy profitability margins, and growth in postpaid accounts. Risks include rising debt levels, intense competition, and capital expenditure pressures. With 83% of analysts rating it a Buy, the stock presents a compelling opportunity for long-term investors, though monitoring competitive dynamics and interest expense trends is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
